WindMIL Therapeutics
1812 Ashland Avenue, 1st Floor
Suite 100
Baltimore
Maryland
21205
United States
Tel: 410-558-1906
Website: https://windmiltherapeutics.com/
About WindMIL Therapeutics
When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and rapid process to extract, activate and expand MILs for future commercial applications. Our lead program is in a large Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILs advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.
YEAR FOUNDED:
2015
LEADERSHIP:
Founders: Ivan Borrello, MD and Kimberly Noonan, PhD
CEO: Brian Halak, PhD
CMO: Dr. Steven Fischkoff
CSO: Kimberly Noonan, PhD
TECHNOLOGY
Please click here for WindMIL's technology.
12 articles with WindMIL Therapeutics
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
Clinical Catch-Up: April 20-24
4/27/2020
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look. -
WindMIL Therapeutics and Cognate BioServices Announce Agreement to Expand MILs Manufacturing Capacity
3/10/2020
WindMIL Therapeutics and Cognate BioServices, Inc. announced they have entered an agreement to expand WindMIL’s clinical manufacturing capacity.
-
WindMIL Therapeutics and Providence Cancer Institute Announce Collaboration to Collect Bone Marrow from Patients with Breast Cancer to Develop Marrow-Infiltrating Lymphocytes (MILs™)
2/11/2020
WindMIL Therapeutics and Providence Cancer Institute announced that the first patient has been identified in an investigator-sponsored study for the collection of bone marrow from patients with breast cancer.
-
WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania
2/5/2020
WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today announced a collaborative pre-clinical research partnership with University of Pennsylvania (Penn) to explore novel chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) in hematological and solid tumor model settings.
-
WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer
12/23/2019
This open-label, multi-center Phase 2a clinical trial will assess the safety and efficacy of MILs alone and in combination with nivolumab.
-
Clinical Catch-Up: December 9-13
12/16/2019
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look. -
WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)
7/9/2019
WindMIL Therapeutics and the University of Michigan Rogel Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with head and neck squamous cell carcinoma.
-
WindMIL Therapeutics Announces $32.5 Million in Series B Financing
6/18/2018
Phase 2, multi-center randomized trial of MILs™ in high-risk multiple myeloma fully enrolled
-
WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing.
-
WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based On Marrow-Infiltrating Lymphocytes
10/5/2017